Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Drug Updates

Subcategories:AnalgesicsBiologics/DMARDs

Diclofenac Patch, Piroxicam Most Effective Topical NSAIDs for Osteoarthritis

Reuters Staff  |  February 28, 2018

NEW YORK (Reuters Health)—Diclofenac patches appear to be the most effective topical nonsteroidal anti-inflammatory drug (NSAID) for osteoarthritis (OA), according to a new systematic review and network meta-analysis. “Topical NSAIDs were effective and safe for OA,” Dr. Weiya Zhang of the University of Nottingham and City Hospital in the UK and colleagues write. “However, confirmation…

The Science Behind Biosimilars

Arthritis & Rheumatology  |  February 27, 2018

Although six biosimilar agents have now been approved by the U.S. Food & Drug Administration for use in rheumatology, scientific, clinical, economic and prescribing questions about the use of biosimilars abound. In fact, at the 2017 ACR/ARHP Annual Meeting in San Diego, Joseph Huffstutter, MD, a rheumatologist in private practice in Chattanooga, Tenn., said that…

What’s Driving the Pain? Alternative Approaches to Pain Management

Richard Quinn  |  February 26, 2018

Patients can experience many different types of pain, and some patients with chronic pain may believe that only opioids will help them. According to Kelly Weselman, MD, the best way to begin managing pain is to determine its root cause and communicate with the patient about the best approach(es) for decreasing their specific pain…

Baricitinib Also Appears Effective in Biologic-Refractory RA

Reuters Staff  |  February 21, 2018

NEW YORK (Reuters Health)—The selective Janus kinase 1 and 2 inhibitor baricitinib appears also to help patients whose rheumatoid arthritis (RA) has not responded adequately to biologic disease-modifying antirheumatic drugs, according to results from the RA-BEACON randomized trial. The previously published overall results from RA-BEACON showed that baricitinib-treated patients had significantly better functional and clinical…

Ferumoxytol Injection Receives New Indication, & Application for GP2017 Moves Ahead

Michele B. Kaufman, PharmD, BCGP  |  February 20, 2018

The FDA recently expanded the indications for ferumoxytol injections to include the treatment of adults with iron-deficiency anemia…

Balancing Opioid Addiction Risk with Pain Management Needs

Larry Beresford  |  February 18, 2018

SAN DIEGO—During a session at the ACR/ARHP 2017 Annual Meeting Nov. 3–8, three representatives from the federal government described several of the government’s varied national strategies and agencies that are tackling pain. All of these strategies are affected by the current national epidemic of opioid overdoses and the need for safer analgesic prescribing. But the…

Marijuana for Rheumatology Patients?

Larry Beresford  |  February 17, 2018

SAN DIEGO—What does cannabis offer to the treatment and management of rheumatology patients and the range of pain states they experience? What do we really know about its long-term effects? These are hard questions to answer with currently available data and a reality nuanced by complications cannabis advocates don’t always recognize, according to two experts…

Etanercept Biosimilar Is Effective, Well-Tolerated for Rheumatoid Arthritis

David Douglas  |  February 16, 2018

NEW YORK (Reuters Health)—The biosimilar LBEC0101 is equivalent to etanercept (Enbrel) in treating patients with rheumatoid arthritis (RA) who respond inadequately to methotrexate, according to researchers from Korea and Japan. As Dr. Yeong-Wook Song tells Reuters Health by email, “LBEC0101 is comparable in efficacy, safety and immunogenicity profile to Enbrel.” The findings, he adds, could…

Health Plans Enact Coverage Policies for Remicade & Infliximab Biosimilars

From the College  |  February 16, 2018

Several major health plans have recently enacted policies regarding coverage status for Remicade (infliximab) and its biosimilars, Inflectra (infliximab-dyyb) and Renflexis (infliximab-abda). Most of these plans are limiting coverage for the biosimilar products to very specific circumstances. Some have also begun denying claims for biosimilars and instructing patients to switch to Remicade. The plans implementing…

Opioid Makers Paid Millions to Advocacy Groups

Nate Raymond  |  February 14, 2018

(Reuters)—Five opioid manufacturers, including OxyContin maker Purdue Pharma LP, have paid more than $10 million to advocacy groups and doctors tied to them, many of whom amplified industry messages supporting the use of the painkillers, a U.S. Senate report said on Monday.1 The report, released by Sen. Claire McCaskill (D-Mo.), says groups who received the…

  • « Previous Page
  • 1
  • …
  • 52
  • 53
  • 54
  • 55
  • 56
  • …
  • 123
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences